Glucagon News and Research

RSS

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024

Fermented foods linked to mental health benefits through gut-brain connection

Researchers explore the mental health benefits of fermented foods on the microbiota-gut-brain axis, highlighting the need for further studies to understand their therapeutic potential.

29 Jan 2024

American Heart Association report highlights disparities in heart disease, calls for equitable healthcare

The American Heart Association's report on heart disease and stroke statistics emphasizes health equity and addresses structural racism in healthcare, revealing disparities in cardiovascular risk factors and disease prevalence among different communities.

29 Jan 2024

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

23 Jan 2024

Dietary factors influencing GLP-1 secretion: a new perspective in diabetes and obesity treatment

Researchers in The American Journal of Clinical Nutrition review the impact of diet on GLP-1 secretion in metabolic conditions like obesity and type 2 diabetes, highlighting its potential in treatment and prevention.

16 Jan 2024

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023

Deep learning designs high-affinity protein binders for bioactive helical peptides

A new study Dec. 18 in Nature reports an AI-driven advance in biotechnology with implications for drug development, disease detection, and environmental monitoring.

18 Dec 2023

Science’s Breakthrough of the Year: GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year.

15 Dec 2023

How safe are GLP-1R agonists in early pregnancy?

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

14 Dec 2023

Cola cure? Study sheds light on soda's potential for common holiday medical emergency

Researchers performed a randomized controlled trial (RCT) to evaluate the safety and effectiveness of cola in relieving esophageal meal bolus impaction.

14 Dec 2023

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

Study explores the intricate gut-brain-liver connection and its impact on health

Study reviews the gut-brain-liver axis, revealing the complex interplay between these organs in health and disease and the implications for therapeutic interventions, focusing on how gut microbiota affects liver and brain health.

10 Dec 2023

New insights into how anti-obesity drugs could help prevent kidney disease

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective.

8 Dec 2023

A class of diabetes medications may reduce the risk of colorectal cancer

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

7 Dec 2023

Sympathetic nervous system and immune interplay: Key to metabolic regulation

A review in Advanced Science explores the interaction between the immune system and the sympathetic nervous system in regulating vital metabolic organs like the pancreas, liver, and adipose tissues. This comprehensive analysis provides insights into the neuroimmune relationships affecting metabolism, offering potential new therapeutic strategies for metabolic diseases.

5 Dec 2023

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023